Inflammatory lipid mediators in adipocyte function and obesity

Nature Reviews Endocrinology

Volumn 6, Issue 2, 2010, Pages 71-82

  Iyer, Abishek ^a   Fairlie, David P ^a   Prins, Johannes B ^a   Hammock, Bruce D ^b   Brown, Lindsay ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; C REACTIVE PROTEIN; EPOXYICOSATRIENOIC ACID; G PROTEIN COUPLED RECEPTOR; LEUKOTRIENE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROSTACYCLIN; PROSTAGLANDIN E2; SALICYLIC ACID; THROMBOCYTE ACTIVATING FACTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ACUTE HEART INFARCTION; ADIPOCYTE; ATHEROSCLEROSIS; BODY WEIGHT; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; ENTERITIS; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ADIPOCYTES; ANTI-INFLAMMATORY AGENTS; FATTY ACIDS; HOMEOSTASIS; HUMANS; IMMUNITY; INFLAMMATION; INSULIN RESISTANCE; LIPIDS; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS; RECEPTORS, G-PROTEIN-COUPLED; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 76149111947     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2009.264     Document Type: Review

References (145)

1. Powell, K. Obesity: the two faces of fat. Nature 447, 525-527 (2007).
2. van Gaal, L. F., Mertens, I. L. & De Block, C. E. Mechanisms linking obesity with cardiovascular disease. Nature 444, 875-880 (2006).
3. Eckel, r. H., Grundy, S. M. & Zimmet, P. Z. The metabolic syndrome. Lancet 365, 1415-1428 (2005).
4. Alberti, K. G., Zimmet, P. & Shaw, J. The metabolic syndrome-a new worldwide definition. Lancet 366, 1059-1062 (2005). (Pubitemid 41338752)
5. Dandona, P., Aljada, A., Chaudhuri, A., Mohanty, P. & Garg, r. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111, 1448-1454 (2005).
6. Mohanty, P. et al. Glucose challenge stimulates reactive oxygen species (rOS) generation by leucocytes. J. Clin. Endocrinol. Metab. 85, 2970-2973 (2000).
7. Aljada, A. et al. Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations. Am. J. Clin. Nutr. 80, 51-57 (2004).
8. Das, U. N. Is obesity an inflammatory condition? Nutrition 17, 953-966 (2001).
9. Unger, r. H. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol. Metab. 14, 398-403 (2003).
10. Pickup, J. C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27, 813-823 (2004).
11. Duncan, B. B. et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52, 1799 - 1805 (2003).
12. Odegaard, J. I. et al. Macrophage-specific PPAr? controls alternative activation and improves insulin resistance. Nature 447, 1116-1120 (2007).
13. Plutzky, J. Expansion and contraction: the mighty, mighty fatty acid. Nat. Med. 15, 618-619 (2009).
14. wellen, K. E. & Hotamisligil, G. S. Inflammation, stress, and diabetes. J. Clin. Invest. 115, 1111-1119 (2005).
15. Bastard, J. P. et al. recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 17, 4-12 (2006).
16. Caballero, A. E. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes. Res. 11, 1278-1289 (2003).
17. visser, M., Bouter, L. M., McQuillan, G. M., wener, M. H. & Harris, T. B. Elevated C-reactive protein levels in overweight and obese adults. JAMA 282, 2131-2135 (1999).
18. Esposito, K. et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289, 1799 - 1804 (2003).
19. ridker, P. M., Buring, J. E., Cook, N. r. & rifai, N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107, 391-397 (2003).
20. Dandona, P. et al. Inhibitory effect of a two day fast on reactive oxygen species (rOS) generation by leucocytes and plasma orthotyrosine and meta-tyrosine concentrations. J. Clin. Endocrinol. Metab. 86, 2899-2902 (2001).
21. Serpillon, S. et al. Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. Am. J. Physiol. Heart Circ. Physiol. 297, H153-H162 (2009).
22. Nijhuis, J. et al. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Obesity 17, 2014-2018 (2009).
23. Dandona. P., Chaudhuri, A., Ghanim, H. & Mohanty, P. Insulin as an anti-inflammatory and antiatherogenic modulator. J. Am. Coll. Cardiol. 53 (Suppl. 1), S14-S20 (2009).
24. Dhindsa, S. et al. Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factorkappaB in mononuclear cells. Metabolism 53, 330-334 (2004).
25. Yuan, M. et al. reversal of obesity- and dietinduced insulin resistance with salicylates or targeted disruption of Ikk?. Science 293, 1673-1677 (2001).
26. renna, N. F., vazquez, M. A., Lama, M. C., Gonzalez, E. S. & Miatello, r. M. Effect of chronic aspirin administration on an experimental model of metabolic syndrome. Clin. Exp. Pharmacol. Physiol. 36, 162-168 (2009).
27. van Kerckhoven, r., Kalkman, E. A., Saxena, P. r. & Schoemaker, r. G. Altered cardiac collagen and associated changes in diastolic function of infarcted rat hearts. Cardiovasc. Res. 46, 316-323 (2000).
28. Larsen, C. M. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526 (2007).
29. Larsen, C. M. et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32, 1663-1668 (2009).
30. wilson, P. w. Evidence of systemic inflammation and estimation of coronary artery disease risk: a population perspective. Am. J. Med. 121 (Suppl. 1), S15-S20 (2008).
31. Libby, P. role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am. J. Med. 121 (Suppl. 1), S21-S31 (2008).
32. Dandona, P. et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J. Clin. Endocrinol. Metab. 88, 4496-4501 (2003).
33. Koh, K. K., Han, S. H. & Quon, M. J. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J. Am. Coll. Cardiol. 46, 1978-1985 (2005).
34. Paraskevas, K. I., Stathopoulos, v. & Mikhailidis, D. P. Pleiotropic effects of statins: implications for a wide range of diseases. Curr. Vasc. Pharmacol. 6, 237-239 (2008).
35. Jankowski, P., Safar, M. E. & Benetos, A. Pleiotropic effects of drugs inhibiting the renin-angiotensin-aldosterone system. Curr. Pharm. Des. 15, 571-584 (2009).
36. Aljada, A. et al. Troglitazone reduces the expression of PPAr? while stimulating that of PPAr? in mononuclear cells in obese subjects. J. Clin. Endocrinol. Metab. 86, 3130-3133 (2001).
37. Mohanty, P. et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. 89, 2728-2735 (2004).
38. Singh, r. et al. Autophagy regulates lipid metabolism. Nature 458, 1131-1135 (2009).
39. Jaworski, K. et al. AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. Nat. Med. 15, 159-168 (2009).
40. Duncan, r. E., Ahmadian, M., Jaworski, K., Sarkadi-Nagy, E. & Sul, H. S. regulation of lipolysis in adipocytes. Annu. Rev. Nutr. 27, 79-101 (2007).
41. Park, K. w., Halperin, D. S. & Tontonoz, P. Before they were fat: adipocyte progenitors. Cell. Metab. 8, 454-457 (2008).
42. Pages, C., Simon, M. F., valet, P. & Saulnier- Blache, J. S. Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat. 64, 1-10 (2001).
43. Ailhaud, G., Guesnet, P. & Cunnane, S. C. An emerging risk factor for obesity: does disequilibrium of polyunsaturated fatty acid metabolism contribute to excessive adipose tissue development? Br. J. Nutr. 100, 461-470 (2008).
44. weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796 - 1808 (2003).
45. Cinti, S. The adipose organ. Prostaglandins Leukot. Essent. Fatty Acids 73, 9-15 (2005).
46. winer, S. et al. Normalization of obesityassociated insulin resistance through immunotherapy. Nat. Med. 15, 921-929 (2009).
47. Hotamisligil, G. S. Inflammation and metabolic disorders. Nature 444, 860-867 (2006).
48. Lumeng, C. N., Maillard, I. & Saltiel, A. r. T-ing up inflammation in fat. Nat. Med. 15, 846-847 (2009).
49. Feuerer, M. et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15, 930-939 (2009).
50. Nishimura, S. et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 15, 914-920 (2009).
51. Nathan, C. Points of control in inflammation. Nature 420, 846-852 (2002).
52. Medzhitov, r. Origin and physiological roles of inflammation. Nature 454, 428-435 (2008).
53. Charriere, G. et al. Preadipocyte conversion to macrophage. Evidence of plasticity. J. Biol. Chem. 278, 9850-9855 (2003).
54. Clement, K. et al. weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J. 18, 1657-1669 (2004).
55. van Dielen, F. M., Buurman, w. A., Hadfoune, M., Nijhuis, J. & Greve, J. w. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J. Clin. Endocrinol. Metab. 89, 4062-4068 (2004).
56. Cottam, D. r. et al. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes. Surg. 14, 589-600 (2004).
57. Nawrocki, A. r. & Scherer, P. E. Keynote review: the adipocyte as a drug discovery target. Drug Discov. Today 10, 1219-1230 (2005).
58. Spiegelman, B. M. PPAr-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47, 507-514 (1998).
59. Amri, E. Z., Bertrand, B., Ailhaud, G. & Grimaldi, P. regulation of adipose cell differentiation. I. Fatty acids are inducers of the AP2 gene expression. J. Lipid Res. 32, 1449-1456 (1991).
60. Aubert, J., Ailhaud, G. & Negrel, r. Evidence for a novel regulatory pathway activated by (carba) prostacyclin in preadipose and adipose cells. FEBS Lett. 397, 117-121 (1996).
61. Ailhaud, G., Grimaldi, P. & Negrel, r. Cellular and molecular aspects of adipose tissue development. Annu. Rev. Nutr. 12, 207-233 (1992).
62. Ailhaud, G. Some new aspects on adipose tissue development. Diabetes Metab. Rev. 8, 3-7 (1992).
63. Spiegelman, B. M. & Flier, J. S. Adipogenesis and obesity: rounding out the big picture. Cell 87, 377-389 (1996).
64. Hauner, H. et al. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J. Clin. Invest. 84, 1663-1670 (1989).
65. Shimizu, T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 49, 123-150 (2009).
66. Ghanim, H. et al. Increase in plasma endotoxin concentrations and the expression of Toll like receptors and suppressor of cytokine signaling-3 in mononuclear cells following a high fat high carbohydrate meal: implications for insulin resistance. Diabetes Care 32, 2281-2287 (2009).
67. Dandona, P., Chaudhuri, A., Ghanim, H. & Mohanty, P. Anti-inflammatory effects of insulin and pro-inflammatory effects of glucose: relevance to the management of acute myocardial infarction and other acute coronary syndromes. Rev. Cardiovasc. Med. 7 (Suppl. 2), S25-S34 (2006).
68. Dandona, P. The link between insulin resistance syndrome and inflammatory markers. Endocr. Pract. 9 (Suppl. 2), 53-57 (2003).
69. Dandona, P., Aljada, A., Chaudhuri, A. & Bandyopadhyay, A. The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosisrelated complications in type 2 diabetes. J. Clin. Endocrinol. Metab. 88, 2422-2429 (2003).
70. williams, E. S., Baylin, A. & Campos, H. Adipose tissue arachidonic acid and the metabolic syndrome in Costa rican adults. Clin. Nutr. 26, 474-482 (2007).
71. Garaulet, M. et al. Site-specific differences in the fatty acid composition of abdominal adipose tissue in an obese population from a Mediterranean area: relation with dietary fatty acids, plasma lipid profile, serum insulin, and central obesity. Am. J. Clin. Nutr. 74, 585-591 (2001).
72. Decsi, T., Molnar, D. & Koletzko, B. Long-chain polyunsaturated fatty acids in plasma lipids of obese children. Lipids 31, 305-311 (1996).
73. Savva, S. C. et al. Association of adipose tissue arachidonic acid content with BMI and overweight status in children from Cyprus and Crete. Br. J. Nutr. 91, 643-649 (2004).
74. weiler, H. A. Dietary supplementation of arachidonic acid is associated with higher whole body weight and bone mineral density in growing pigs. Pediatr. Res. 47, 692-697 (2000).
75. Jensen, C. L. et al. Effect of dietary linoleic/ alpha-linolenic acid ratio on growth and visual function of term infants. J. Pediatr. 131, 200-209 (1997).
76. Duncan, r. E., Sarkadi-Nagy, E., Jaworski, K., Ahmadian, M. & Sul, H. S. Identification and functional characterization of adipose-specific phospholipase A2 (AdPLA). J. Biol. Chem. 283, 25428-25436 (2008).
77. Ii, H., Hatakeyama, S., Tsutsumi, K., Sato, T. & Akiba, S. Group IvA phospholipase A2 is associated with the storage of lipids in adipose tissue and liver. Prostaglandins Other Lipid Mediat. 86, 12-17 (2008).
78. Satake, Y. et al. role of group v phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption. J. Biol. Chem. 279, 16488-16494 (2004).
79. Balsinde, J., winstead, M. v. & Dennis, E. A. Phospholipase A2 regulation of arachidonic acid mobilization. FEBS Lett. 531, 2-6 (2002).
80. Levick, S. et al. Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats. J. Immunol. 176, 7000-7007 (2006).
81. Degousee, N. et al. Groups, Iv, v, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J. Biol. Chem. 277, 5061-5073 (2002).
82. Harizi, H., Corcuff, J. B. & Gualde, N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol. Med. 14, 461-469 (2008).
83. Narumiya, S. & FitzGerald, G. A. Genetic and pharmacological analysis of prostanoid receptor function. J. Clin. Invest. 108, 25-30 (2001).
84. Gupta, r. A. et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc. Natl Acad. Sci. USA 97, 13275-13280 (2000).
85. Forman, B. M. et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAr gamma. Cell 83, 803-812 (1995).
86. Pierce, K. L. & regan, J. w. Prostanoid receptor heterogeneity through alternative mrNA splicing. Life Sci. 62, 1479-1483 (1998).
87. Sugimoto, Y. & Narumiya, S. Prostaglandin E receptors. J. Biol. Chem. 282, 11613-11617 (2007).
88. vane, J. r., Bakhle, Y. S. & Botting, r. M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38, 97-120 (1998).
89. Bos, C. L., richel, D. J., ritsema, T., Peppelenbosch, M. P. & versteeg, H. H. Prostanoids and prostanoid receptors in signal transduction. Int. J. Biochem. Cell Biol. 36, 1187-1205 (2004).
90. Kim, S. & Moustaid-Moussa, N. Secretory, endocrine and autocrine/paracrine function of the adipocyte. J. Nutr. 130 (Suppl.), S3110-S3115 (2000).
91. Shillabeer, G., Kumar, v., Tibbo, E. & Lau, D. C. Arachidonic acid metabolites of the lipoxygenase as well as the cyclooxygenase pathway may be involved in regulating preadipocyte differentiation. Metabolism 47, 461-466 (1998).
92. Fain, J. N., Leffler, C. w. & Bahouth, S. w. Eicosanoids as endogenous regulators of leptin release and lipolysis by mouse adipose tissue in primary culture. J. Lipid Res. 41, 1689-1694 (2000).
93. Fain, J. N. & Bahouth, S. w. regulation of leptin release by mammalian adipose tissue. Biochem. Biophys. Res. Commun. 274, 571-575 (2000).
94. Enomoto, N. et al. Kupffer cell-derived prostaglandin E2 is involved in alcohol-induced fat accumulation in rat liver. Am. J. Physiol. Gastrointest. Liver Physiol. 279, G100-G106 (2000).
95. Perez, S., Aspichueta, P., Ochoa, B. & Chico, Y. The 2-series prostaglandins suppress vLDL secretion in an inflammatory conditiondependent manner in primary rat hepatocytes. Biochim. Biophys. Acta 1761, 160-171 (2006).
96. Massiera, F. et al. Arachidonic acid and prostacyclin signaling promote adipose tissue development: a human health concern? J. Lipid Res. 44, 271-279 (2003).
97. Mazid, M. A. et al. Endogenous 15-deoxy-?12, 14-prostaglandin J2 synthesized by adipocytes during maturation phase contributes to upregulation of fat storage. FEBS Lett. 580, 6885-6890 (2006).
98. vassaux, G., Negrel, r., Ailhaud, G. & Gaillard, D. Proliferation and differentiation of rat adipose precursor cells in chemically defined medium: differential action of anti-adipogenic agents. J. Cell Physiol. 161, 249-256 (1994).
99. Liu, L. & Clipstone, N. A. Prostaglandin F2? inhibits adipocyte differentiation via a G?q-calcium-calcineurin-dependent signaling pathway. J. Cell Biochem. 100, 161-173 (2007).
100. Goodwill, A. G., James, M. E. & Frisbee, J. C. Increased vascular thromboxane generation impairs dilation of skeletal muscle arterioles of obese Zucker rats with reduced oxygen tension. Am. J. Physiol. Heart Circ. Physiol. 295, H1522-H1528 (2008).
101. Homaidan, F. r., Chakroun, I., Haidar, H. A. & El-Sabban, M. E. Protein regulators of eicosanoid synthesis: role in inflammation. Curr. Protein Pept. Sci. 3, 467-484 (2002).
102. Brink, C. Leukotriene receptors: state of the art. Adv. Exp. Med. Biol. 525, 7-10 (2003).
103. Camara, N. O., Martins, J. O., Landgraf, r. G. & Jancar, S. Emerging roles for eicosanoids in renal diseases. Curr. Opin. Nephrol. Hypertens. 18, 21-27 (2009).
104. Back, M., Sultan, A., Ovchinnikova, O. & Hansson, G. K. 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ. Res. 100, 946-949 (2007).
105. Madsen, L. et al. Adipocyte differentiation of 3T3-L1 preadipocytes is dependent on lipoxygenase activity during the initial stages of the differentiation process. Biochem. J. 375, 539-549 (2003).
106. Nunemaker, C. S. et al. 12-Lipoxygenaseknockout mice are resistant to inflammatory effects of obesity induced by western diet. Am. J. Physiol. Endocrinol. Metab. 295, E1065-E1075 (2008).
107. Maya-Monteiro, C. M. et al. Leptin induces macrophage lipid body formation by a phosphatidylinositol 3-kinase- and mammalian target of rapamycin-dependent mechanism. J. Biol. Chem. 283, 2203-2210 (2008).
108. Jozsef, L., Zouki, C., Petasis, N. A., Serhan, C. N. & Filep, J. G. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc. Natl Acad. Sci. USA 99, 13266-13271 (2002).
109. Perretti, M. et al. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat. Med. 8, 1296-1302 (2002).
110. Serhan, C. N. et al. resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037 (2002).
111. Serhan, C. N. & Savill, J. resolution of inflammation: the beginning programs the end. Nat. Immunol. 6, 1191-1197 (2005).
112. Serhan, C. N., Chiang, N. & van Dyke, T. E. resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8, 349-361 (2008).
113. Inceoglu, B., Schmelzer, K. r., Morisseau, C., Jinks, S. L. & Hammock, B. D. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat. 82, 42-49 (2007).
114. Spector, A. A. & Norris, A. w. Action of epoxyeidosatrienoic acids on cellular function. Am. J. Physiol. Cell. Physiol. 292, C996-C1012 (2007).
115. De Taeye, B. M. et al. Expression and regulation of soluble epoxide hydrolase in adipose tissue. Obesity doi:10.1038/oby.2009.227.
116. Ai, D. et al. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc. Natl Acad. Sci. USA 104, 9018-9023 (2007).
117. Hammock, B. D. & Ota, K. Differential induction of cytosolic epoxide hydrolase, microsomal epoxide hydrolase, and glutathione S-transferase activities. Toxicol. App. Pharmacol. 71, 254-265 (1983).
118. Campbell, w. B. New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. Trends Pharmacol. Sci. 21, 125-127 (2000).
119. Node, K. et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276-1279 (1999).
120. Schmelzer, K. r. et al. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc. Natl Acad. Sci. USA 103, 13646-13651 (2006).
121. Lee, C. r. et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis risk in Communities (ArIC) study. Hum. Mol. Genet. 15, 1640-1649 (2006).
122. Ohtoshi, K. et al. Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. Biochem. Biophys. Res. Commun. 331, 347-350 (2005).
123. Burdon, K. P. et al. Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study. Diab. Vasc. Dis. Res. 5, 128-134 (2008).
124. Gountopoulou, A., Leondaritis, G., Galanopoulou, D. & Mavri-vavayanni, M. TNF? is a potent inducer of platelet-activating factor synthesis in adipocytes but not in preadipocytes. Differential regulation by PI3K. Cytokine 41, 174-181 (2008).
125. Samad, F., Hester, K. D., Yang, G., Hannun, Y. A. & Bielawski, J. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 55, 2579-2587 (2006).
126. Di Marzo, v. Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discov. 7, 438-455 (2008).
127. Kudolo, G. B., Bressler, P. & DeFronzo, r. A. Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment. J. Lipid Mediat. Cell Signal. 17, 97-113 (1997).
128. Okada, T. et al. Platelet-activating factor acetylhydrolase concentration in children with abdominal obesity. Arterioscler. Thromb. Vasc. Biol. 26, e40-e41 (2006).
129. Jones, D. End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat. Rev. Drug Discov. 7, 961-962 (2008).
130. Cooke, D. & Bloom, S. The obesity pipeline: current strategies in the development of antiobesity drugs. Nat. Rev. Drug Discov. 5, 919-931 (2006).
131. Janero, D. r. & Makriyannis, A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin. Emerg. Drugs 14, 43-65 (2009).
132. Yudkin, J. S., Kumari, M., Humphries, S. E. & Mohamed-Ali, v. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148, 209-214 (2000).
133. Xu, H. et al. Chronic inflammation in fat plays a crucial role in the development of obesityrelated insulin resistance. J. Clin. Invest. 112, 1821-1830 (2003).
134. wang, Y. X. et al. Peroxisome-proliferatoractivated receptor delta activates fat metabolism to prevent obesity. Cell 113, 159-170 (2003).
135. rajala, M. w., Obici, S., Scherer, P. E. & rossetti, L. Adipose-derived resistin and gutderived resistin-like molecule-beta selectively impair insulin action on glucose production. J. Clin. Invest. 111, 225-230 (2003).
136. Dandona, P., Aljada, A. & Bandyopadhyay, A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 25, 4-7 (2004).
137. Cai, D. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-? and NF-kB. Nat. Med. 11, 183-190 (2005).
138. Arkan, M. C. et al. IKK-? links inflammation to obesity-induced insulin resistance. Nat. Med. 11, 191-198 (2005).
139. Masoudi, F. A. et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111, 583-590 (2005).
140. Christiansen, T., richelsen, B. & Bruun, J. M. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int. J. Obes. (Lond.) 29, 146-150 (2005).
141. Shoelson, S. E., Herrero, L. & Naaz, A. Obesity, inflammation, and insulin resistance. Gastroenterology 132, 2169-2180 (2007).
142. Kim, F. et al. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ. Res. 100, 1589-1596 (2007).
143. Heilbronn, L. K. & Campbell, L. v. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr. Pharm. Des. 14, 1225-1230 (2008).
144. Cani, P. D. et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470-1481 (2008).
145. rocha, v. Z. et al. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ. Res. 103, 467-476 (2008).